Recent Technical and Business Updates – Research on FormFactor, Calithera Biosciences, Ocular Therapeutix and Ultralife

NEW YORK, NY / ACCESSWIRE / November 2, 2015 / Moments ago, Trader’s Choice released new research updates concerning several important developing situations including the following equities: FormFactor, Inc (NASDAQ: FORM), Calithera Biosciences, Inc. (NASDAQ: CALA), Ocular Therapeutix, Inc. (NASDAQ: OCUL) and Ultralife Corporation (NASDAQ: ULBI). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.

To access our full PDF reports for free, please visit the links below.

============

Full PDF DOWNLOAD Links

(You may have to copy and paste the links into your browser)

FORM Research Report: http://www.traders-choice.com/pdf?s=FORM

CALA Research Report: http://www.traders-choice.com/pdf?s=CALA

OCUL Research Report: http://www.traders-choice.com/pdf?s=OCUL

ULBI Research Report: http://www.traders-choice.com/pdf?s=ULBI

============

Highlights from today’s reports include:

On Friday, October 30, 2015, the NASDAQ Composite ended at 5,053.75, down 0.40%, the Dow Jones Industrial Average edged 0.52% lower to finish the day at 17,663.54, and the S&P 500 closed at 2,079.36, down 0.48%.

– FormFactor Inc’s stock decreased 3.85% to close Friday’s session at USD 8.24. The company’s shares fluctuated in the range of USD 8.21 and USD 8.58. A total of 0.58 million shares exchanged hands, which surpassed its 50-day daily average volume of 0.29 million shares and was above its 52-week average volume of 0.38 million shares. Over the last three days, FormFactor Inc’s shares have advanced 9.87% and in the past one week, it has moved up 8.71%. Furthermore, over the last three months, the stock has gained 13.97% while in the past six months the stock has shed 2.94%. The stock is at a price to book ratio of 1.70 against a historical PB ratio of 1.69. Additionally, the stock is trading at a price to cash flow ratio of 12.09 and price to sales ratio of 1.77. Recently on October 28, 2015, FormFactor Inc announced that its third quarter fiscal 2015 revenues were USD 65.9 million, down 11% from USD 73.9 million in the prior year quarter. Additionally, the Company reported GAAP net loss of USD 2.5 million during the quarter, compared to a net loss of USD 0.3 million in Q3FY14.

– Calithera Biosciences Inc’s stock slipped 2.18% to close Friday’s session at USD 8.54. The company’s shares oscillated between USD 8.25 and USD 8.94. The stock recorded a trading volume of 0.21 million shares, which was below its 50-day daily average volume of 0.33 million shares and below its 52-week average volume of 0.39 million shares. Over the last five days, Calithera Biosciences Inc’s shares have advanced 15.56% and in the past one month, it has gained a momentum of 57.27%. In addition, over the last three months, the stock has gained 15.41% while year to date, the shares have shed 57.72%. The stock is trading at 50-Day Moving Average of USD 6.56 and 200-Day Moving Average of USD 10.57. Recently, on October 30, 2015, the Company announced that its third quarter 2015 financial results will be released on Monday, November 9, 2015.

– In line with the broader market movement, Ocular Therapeutix Inc’s stock declined 8.00% to close Friday’s session at USD 8.63. The share price vacillated between USD 8.42 and USD 9.25. The stock recorded a trading volume of 0.41 million shares, which was above its 50-day daily average volume of 0.28 million shares and above its 52-week average volume of 0.23 million shares. Over the last three days, Ocular Therapeutix Inc’s shares have advanced 14.61% and in the past one week it has moved up 20.19%. Moreover, in the last six months, the stock has lost 60.74% and year to date, the shares have shed 63.31%. Recently, on October 22, 2015, Ocular Therapeutix Inc announced topline efficacy results from a Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone) 0.4 mg, Intracanalicular Depot for the treatment of allergic conjunctivitis. The trial results reflected that DEXTENZA has successfully met primary endpoint for treatment of ocular itching associated with allergic conjunctivitis.

– Ultralife Corp’s stock edged lower by 1.02% to close Friday’s session at USD 6.78, in line with the sluggish momentum in the broader market. The company’s shares oscillated between USD 6.63 and USD 7.08. The stock recorded a trading volume of 0.14 million shares, which was above its 50-day daily average volume of 0.06 million shares and above its 52-week average volume of 0.03 million shares. Over the last three days, Ultralife Corp’s shares have advanced 9.00% and in the past one week it has moved up 5.94%. Furthermore, over the last three months, the stock has gained 66.58% and in the past six months, the shares have picked up 65.37%. Further, the company is trading at a price to earnings ratio of 62.30, a price to book ratio of 1.60, a price to cash flow ratio of 17.98 and price to sales ratio of 1.44. Recently, on October 29, 2015, Ultralife Corp announced its financial results for third quarter of fiscal 2015. During the quarter, the Company’s revenue grew 19% YoY to USD 19.0 million. Meanwhile, net income was USD 1.0 million, or USD 0.07 per share during Q3 FY15, compared to a net loss of USD 0.3 million, or USD 0.02 per share, in Q3FY14.

About Trader’s Choice:

Trader’s Choice (“TC”) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. TC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TC has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer (collectively referred to as the “Production Team”) in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY

TC, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.traders-choice.com/.

RESTRICTIONS

TC is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press (at) traders-choice.com

SOURCE: Trader’s Choice

ReleaseID: 433151